Legend Biotech (LEGN) Stock Forecast: What Could Drive It in 2026
Short answer
What is actually driving Legend Biotech (LEGN) right now is CARVYKTI commercial ramp: CARVYKTI net trade sales reached about $1.9 billion in 2025 and rose roughly 62 percent year over year in Q1 2026, with ex-US sales growing far faster than US sales off a smaller base. Revenue (TTM, collaboration/license) is ~$1.1B. If that keeps playing out, the setup is favourable; the risk to it is legend's value is heavily concentrated in one product, CARVYKTI, and in one partner, Johnson & Johnson, which shares profits and controls much of the commercial engine. No one can predict where LEGN trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive Legend Biotech (LEGN) higher?
1. CARVYKTI commercial ramp
CARVYKTI net trade sales reached about $1.9 billion in 2025 and rose roughly 62 percent year over year in Q1 2026, with ex-US sales growing far faster than US sales off a smaller base. The franchise is now available in 18 markets and more than 300 sites, and management has pointed to expanding manufacturing capacity as the key throughput lever. Continued volume growth is the single largest driver of the story.
2. Move to earlier lines of therapy
Approvals expanding CARVYKTI into earlier treatment lines widen the eligible patient pool well beyond heavily pretreated patients. Earlier use, if supported by durable outcomes data, is what supports the multibillion-dollar sales trajectory analysts model. Adoption depends on physician comfort with CAR-T logistics versus off-the-shelf alternatives.
3. Path to profitability
Legend narrowed its net loss substantially in Q1 2026 (adjusted net loss of about $10.5 million) and reported a full-year 2025 adjusted net loss of roughly $33 million, signaling it is approaching adjusted breakeven. The J&J profit split means margin leverage builds as CARVYKTI scales. Reaching and sustaining GAAP profit remains the central proof point investors are watching.
4. Pipeline optionality
Beyond CARVYKTI, Legend is advancing earlier-stage cell therapies including next-generation and solid-tumor programs. These are largely unproven and years from meaningful revenue, so they function as long-dated optionality rather than a current earnings contributor. Any clinical readout that de-risks a second franchise would matter given the current single-product concentration.
What could weigh on LEGN?
Legend's value is heavily concentrated in one product, CARVYKTI, and in one partner, Johnson & Johnson, which shares profits and controls much of the commercial engine. The multiple-myeloma market is increasingly crowded, with competing CAR-T therapies like Bristol Myers Squibb's Abecma and off-the-shelf BCMA bispecific antibodies such as J&J's Tecvayli and Pfizer's Elrexfio that avoid CAR-T's manufacturing and logistics burden. CAR-T therapies also carry serious safety considerations and manufacturing and capacity constraints that can cap growth. The company is only near breakeven and still posts losses, so any sales miss, pricing pressure, or safety signal can move the stock sharply. As a China-founded, US-listed ADR, it also carries geopolitical, supply-chain, and regulatory exposure that pure-play US biotechs do not.
Where LEGN trades today
A forecast starts from where the stock actually is. These are LEGN's current figures, not a projection: the drivers and risks above are what would move them.
Snapshot for LEGN as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
How to think about a LEGN forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the LEGN guide and whether LEGN is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the LEGN outlook
The bottom line: what is driving Legend Biotech (LEGN) is CARVYKTI commercial ramp, with revenue (ttm, collaboration/license) at ~$1.1B. If that keeps playing out the setup is favourable; the risk is legend's value is heavily concentrated in one product, CARVYKTI, and in one partner, Johnson & Johnson, which shares profits and controls much of the commercial engine. No one can predict the price, so treat any LEGN forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around LEGN with Walnut
Use Legend Biotech as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for Legend Biotech (LEGN)?
+
No one can reliably predict where LEGN will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push Legend Biotech higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive LEGN higher?
+
The main growth drivers are CARVYKTI commercial ramp; Move to earlier lines of therapy; Path to profitability. Whether they play out is the real question, not a guaranteed path.
What are the risks to LEGN?
+
Legend's value is heavily concentrated in one product, CARVYKTI, and in one partner, Johnson & Johnson, which shares profits and controls much of the commercial engine. The multiple-myeloma market is increasingly crowded, with competing CAR-T therapies like Bristol Myers Squibb's Abecma and off-the-shelf BCMA bispecific antibodies such as J&J's Tecvayli and Pfizer's Elrexfio that avoid CAR-T's manufacturing and logistics burden. CAR-T therapies also carry serious safety considerations and manufacturing and capacity constraints that can cap growth. The company is only near breakeven and still posts losses, so any sales miss, pricing pressure, or safety signal can move the stock sharply. As a China-founded, US-listed ADR, it also carries geopolitical, supply-chain, and regulatory exposure that pure-play US biotechs do not.
Will LEGN stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. Legend Biotech's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is LEGN a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the LEGN "is it a buy?" page for a framework. Walnut is not an investment adviser.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.